MLYS
What one share of Mineralys Therapeutics holds
Pharmaceutical Preparations
We are a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA).
Mineralys Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.38 |
|---|---|
| Cash and investments | $1.56 |
| Debt | $0.00 |
| Book value | $6.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$5.77 | — | −$5.66 | — | −$8.14 |
| 2023 | — | −$1.99 | $0.00 | −$2.24 | — | $5.86 |
| 2024 | — | −$3.66 | $0.00 | −$3.43 | — | $3.84 |
| 2025 | — | −$2.29 | $0.00 | −$2.11 | — | $7.93 |